William Mack & Associates’s AbbVie ABBV Stock Holding History

William Mack & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Buy	+970	New	+$209K	0.09%	98
2026 Q1	–	Sell	-1,054	Closed	-$241K	–	74
2025 Q4	$241K	Buy	1,054 +80	+8%	+$18.2K	0.11%	72
2025 Q3	$226K	Buy	+974	New	+$198K	0.12%	76

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

William Mack & Associates's ABBV Position: Q2 2026 in Review

William Mack & Associates opened a new position in AbbVie (ABBV) in Q2 2026: 970 shares worth $244K. The stake represents 0.09% of the portfolio and ranks #98 among its holdings. This is a return to the name: William Mack & Associates previously reported a position in ABBV as recently as Q4 2025.

William Mack & Associates first reported a position in ABBV in Q3 2025 and has held it in 3 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

William Mack & Associates held 970 shares of AbbVie worth $244K as of Q2 2026.
AbbVie was a new William Mack & Associates position in Q2 2026.
AbbVie made up 0.09% of William Mack & Associates's portfolio in Q2 2026, its #98 holding.
William Mack & Associates first reported a position in AbbVie in Q3 2025 and has held it in 3 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on William Mack & Associates's 13F filing for Q2 2026, filed 10 Jul 2026.